【摘要】 目的 评价奎硫平与氟哌啶醇治疗精神分裂症的疗效及安全性。 方法 将59例精神分裂症患者随机分为两组，研究组30例，口服奎硫平治疗;对照组29例，口服氟哌啶醇治疗。观察8 w。于治疗前及治疗第2 w、4 w、8 w末采用潘氏量表评定临床疗效，副反应量表评定不良反应。 结果 治疗8 w末研究组有效率为90%，对照组为75.9%(U=2.089，P<0.05)。潘氏量表评分治疗2 w末起两组总分、阳性症状分及研究组一般精神病理分，4 w末起研究组阴性症状分及对照组一般精神病理分均较治疗前有显著下降(P均<0.01);8 w末对照组阴性症状分虽较治疗前有所下降，但无显著性差异(P>0.05);研究组治疗2 w末一般精神病理分、4 w末总分及阴性症状分均较对照组下降显著(P<0.01～0.05)，阳性症状分各时点与对照组比较均无显著性差异(P均>0.05)。治疗8 w末副反应量表评分研究组显著低于对照组(t=-4.016，P<0.01)。结论 奎硫平治疗精神分裂症的疗效优于氟哌啶醇，不良反应发生率低，且程度较轻，安全性高，依从性好。
【关键词】 精神分裂症;奎硫平;氟哌啶醇;疗效
A control study of quetiapine vs. haloperidol in the treatment of schizophrenia
Tao Jianqing，Liu Jiabin，Liang Yazhi，et al
(Psycho-Rehabilitation Center，the People’s Hospital of ChuangAutonomous Region，NanNing 530021，Guangxi，China)
【Abstract】 Objective To evaluate the efficacy and safety of quetiapine vs. haloperidol in the treatment of schizophrenia. Methods 59 schizophrenics were randomly assigned into research group(n=30) taking orally quetiapine and control group(n=29) doing haloperidol for 8 weeks. Clinical effects were assessed with the Positive and Negative Syndrome Scale(PANSS) and adverse effects with the Treatment Emergent Symptom Scale(TESS) at baseline and at the end of the 2nd，4th，6th and 8th week treatment. Results At the end of the 8th week，effective rates were respectively 90% in the research and 75.9% in the control group(P<0.05). According to the PANSS，the total and positive symptoms scores of both groups and general psychopathological score of the research since the end of the 2nd week，and negative symptoms score of the research and general psychopathological score of the control since the end of the 4th lowered more significantly compared with pretreatment(all P<0.01);at the end of the 8th week，total score and negative symptoms scores lowered compared with pretreatment compared with pretreatment but differences were not significant in the control(P>0.05);general spychopathol
[1] [2] [3] [4] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 临床医学论文 >> 正文